| scholarly article | Q13442814 |
| P50 | author | Gerald Watts | Q71943021 |
| Jing Pang | Q51018104 | ||
| Dick Chan | Q58842465 | ||
| P2860 | cites work | Apolipoprotein C-III: understanding an emerging cardiovascular risk factor | Q24318657 |
| Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline | Q24608464 | ||
| Standards of medical care in diabetes--2012 | Q24632533 | ||
| Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial | Q24633239 | ||
| Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association | Q28235865 | ||
| Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 | ||
| Alogliptin after acute coronary syndrome in patients with type 2 diabetes | Q28297690 | ||
| 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines | Q28301815 | ||
| Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia | Q28565000 | ||
| Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial | Q74293220 | ||
| Severe hypertriglyceridemia influenced by alcohol (SHIBA) | Q83230605 | ||
| Effects of nutrients on postprandial lipemia | Q83398118 | ||
| A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy | Q83737936 | ||
| Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study) | Q84595387 | ||
| Selective whole blood lipoprotein apheresis to prevent pancreatitis in drug refractory hypertriglyceridemia | Q84982914 | ||
| Hypertriglyceridemic waist phenotype is associated with decreased insulin sensitivity and incident diabetes in elderly men | Q86434735 | ||
| The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 | Q94500852 | ||
| Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes | Q46210895 | ||
| Using Mendelian randomization to determine causative factors in cardiovascular disease | Q46801575 | ||
| Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis | Q46810855 | ||
| Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans | Q46919674 | ||
| Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study | Q46945399 | ||
| Lifestyle intervention leading to moderate weight loss normalizes postprandial triacylglycerolemia despite persisting obesity. | Q47411581 | ||
| Insulin secretion is increased in non-diabetic subjects with fasting hypertriglyceridaemia. | Q51347839 | ||
| Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. | Q51352959 | ||
| n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. | Q51355736 | ||
| Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. | Q51361433 | ||
| Hypertriglyceridemic waist: a simple clinical phenotype associated with coronary artery disease in women. | Q51371091 | ||
| Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. | Q51375119 | ||
| Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. | Q51381989 | ||
| Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders. | Q51579221 | ||
| Postprandial cholesteryl ester transfer and high density lipoprotein composition in normotriglyceridemic non-insulin-dependent diabetic patients. | Q51582980 | ||
| Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. | Q51679983 | ||
| Relation of the "hypertriglyceridemic waist" phenotype to earlier manifestations of coronary artery disease in patients with glucose intolerance and type 2 diabetes mellitus. | Q53743539 | ||
| Four-year follow-up after two-year dietary interventions. | Q55056728 | ||
| Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment | Q67720940 | ||
| Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B | Q70666068 | ||
| Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis | Q39635925 | ||
| Triglycerides are more important in atherosclerosis than epidemiology has suggested | Q40828853 | ||
| Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis | Q41762672 | ||
| Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome | Q42646132 | ||
| Usefulness of hypertriglyceridemic waist phenotype in type 2 diabetes mellitus to predict the presence of coronary artery disease as assessed by computed tomographic coronary angiography | Q42787248 | ||
| Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial | Q42928497 | ||
| Fibrates in CVD: a step towards personalised medicine | Q43050781 | ||
| An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design | Q43077342 | ||
| Plant stanol supplementation decreases serum triacylglycerols in subjects with overt hypertriglyceridemia | Q43244614 | ||
| Plasmapheresis in the management of severe hypertriglyceridemia | Q43473492 | ||
| Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). | Q43636911 | ||
| Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. | Q43826699 | ||
| Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease | Q43834212 | ||
| Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial | Q44067956 | ||
| Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content | Q44473913 | ||
| Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. | Q45142621 | ||
| Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta | Q45146790 | ||
| Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency | Q45882936 | ||
| RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet | Q29030043 | ||
| Evaluation of methods for the measurement of low-density lipoprotein cholesterol. | Q29547378 | ||
| Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy | Q29616232 | ||
| Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group | Q29619842 | ||
| Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials | Q29622947 | ||
| Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial | Q30080004 | ||
| Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. | Q30385604 | ||
| Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes | Q30548796 | ||
| Hypertriglyceridemic waist might be an alternative to metabolic syndrome for predicting future diabetes mellitus | Q31138509 | ||
| Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. | Q33305306 | ||
| Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. | Q33576435 | ||
| HDL metabolism in hypertriglyceridemic states: an overview | Q33746644 | ||
| Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials | Q33776194 | ||
| Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial | Q33789084 | ||
| Effects of combination lipid therapy in type 2 diabetes mellitus | Q33889260 | ||
| Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial | Q34008233 | ||
| Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis | Q34027392 | ||
| The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study | Q34142618 | ||
| Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial | Q34158442 | ||
| Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). | Q34161324 | ||
| Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management | Q34181381 | ||
| Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin | Q34190482 | ||
| Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). | Q34193530 | ||
| ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). | Q34196167 | ||
| Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors | Q34209341 | ||
| Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). | Q34214164 | ||
| The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. | Q34215047 | ||
| Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. | Q34245974 | ||
| Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial | Q34293369 | ||
| Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence | Q34301772 | ||
| Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial | Q34311144 | ||
| Obesity: a rational target for managing diabetes mellitus | Q34349487 | ||
| The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management | Q34359967 | ||
| ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab | Q34368081 | ||
| Genetic determinants of plasma triglycerides | Q34503333 | ||
| Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials | Q34575937 | ||
| Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis | Q34578231 | ||
| n-3 fatty acids in patients with multiple cardiovascular risk factors | Q34651597 | ||
| Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease | Q34687253 | ||
| Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation | Q34765654 | ||
| Extended-release niacin or ezetimibe and carotid intima-media thickness. | Q35013008 | ||
| Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes | Q35060170 | ||
| Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis | Q35346665 | ||
| The association of hypertriglyceridemic waist phenotype with type 2 diabetes mellitus among individuals with first relative history of diabetes. | Q35544642 | ||
| Lipid-lowering therapy and macrovascular disease in diabetes mellitus | Q35840897 | ||
| The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus | Q35871965 | ||
| Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis | Q36028563 | ||
| REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia | Q36314438 | ||
| Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus | Q36538599 | ||
| HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment | Q36806044 | ||
| Poorly controlled type 2 diabetes complicated by an episode of severe hypertriglyceridaemia-induced pancreatitis. | Q36818185 | ||
| Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology? | Q36969065 | ||
| Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study | Q37105236 | ||
| Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia | Q37135042 | ||
| Smoking, inflammatory patterns and postprandial hypertriglyceridemia | Q37144675 | ||
| Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes | Q37364955 | ||
| Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials | Q37367505 | ||
| Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). | Q37390626 | ||
| Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia | Q37613167 | ||
| Cardiovascular effects of marine omega-3 fatty acids. | Q37773594 | ||
| Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis | Q37807253 | ||
| Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. | Q37825946 | ||
| Effects of lifestyle interventions and long-term weight loss on lipid outcomes - a systematic review | Q37849342 | ||
| Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis | Q37876983 | ||
| Management of severe hypertriglyceridemia in the hospital: a review | Q37962895 | ||
| Effects of ethanol intake on lipoproteins | Q37986600 | ||
| Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. | Q38076370 | ||
| Severe hypertriglyceridaemia in Type 2 diabetes mellitus: beneficial effect of continuous insulin infusion | Q38082482 | ||
| An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia | Q38169282 | ||
| Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study | Q38473168 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 165-175 | |
| P577 | publication date | 2014-04-01 | |
| P1433 | published in | World journal of diabetes | Q27723539 |
| P1476 | title | Origin and therapy for hypertriglyceridaemia in type 2 diabetes | |
| P478 | volume | 5 |
| Q30869985 | A network biology workflow to study transcriptomics data of the diabetic liver |
| Q36188834 | Cordyceps militaris Treatment Preserves Renal Function in Type 2 Diabetic Nephropathy Mice |
| Q33559285 | Depression contributing to dyslipidemic cardiovascular risk in the metabolic syndrome |
| Q59799467 | The characteristic, antioxidative and multiple organ protective of acidic-extractable mycelium polysaccharides by Pleurotus eryngii var. tuoliensis on high-fat emulsion induced-hypertriglyceridemic mice |
Search more.